EP1429747A4 - CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE - Google Patents
CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDEInfo
- Publication number
- EP1429747A4 EP1429747A4 EP01952548A EP01952548A EP1429747A4 EP 1429747 A4 EP1429747 A4 EP 1429747A4 EP 01952548 A EP01952548 A EP 01952548A EP 01952548 A EP01952548 A EP 01952548A EP 1429747 A4 EP1429747 A4 EP 1429747A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- biguanide
- pioglitazone hydrochloride
- core formulation
- formulation
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/501—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2001/021615 WO2003005995A1 (en) | 2001-07-10 | 2001-07-10 | Core formulation comprising pioglitazone hydrochloride and a biguanide |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1429747A1 EP1429747A1 (en) | 2004-06-23 |
EP1429747A4 true EP1429747A4 (en) | 2005-01-05 |
Family
ID=21742689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01952548A Withdrawn EP1429747A4 (en) | 2001-07-10 | 2001-07-10 | CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1429747A4 (es) |
JP (1) | JP2004536843A (es) |
AU (1) | AU2001273289B2 (es) |
CA (1) | CA2453775A1 (es) |
MX (1) | MXPA04000180A (es) |
WO (1) | WO2003005995A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2453784A1 (en) * | 2001-07-10 | 2003-01-23 | Kos Life Sciences, Inc. | A core formulation |
EP1552832A1 (en) * | 2002-07-11 | 2005-07-13 | Takeda Pharmaceutical Company Limited | Process for producing coated preparation |
NZ541749A (en) | 2003-01-29 | 2009-06-26 | Takeda Pharmaceutical | Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material |
WO2005013942A1 (en) * | 2003-07-19 | 2005-02-17 | Warren Ward | Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
GB0316940D0 (en) * | 2003-07-19 | 2003-08-27 | Ward Warren | Treatment of skin and other medical conditions |
US20070078170A1 (en) * | 2003-08-28 | 2007-04-05 | Khanduri Chandra H | Process for the preparation of pioglitazone |
US20060153889A1 (en) * | 2005-01-10 | 2006-07-13 | Friel Francis M | Discontinuous surface coating for particles |
MXPA05014092A (es) * | 2005-12-20 | 2007-06-20 | Leopoldo De Jesus Espinosa Abdala | Composiciones farmaceuticas que comprenden sustancias derivadas de la tiazolidinedionas combinadas con una biguanida para su uso en diabetes mellitus tipo 2. |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041842A1 (en) * | 1996-05-09 | 1997-11-13 | The Trustees Of The University Of Pennsylvania | Hollow bone mineral-like calcium phosphate particles |
WO1999003477A1 (en) * | 1997-07-18 | 1999-01-28 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
WO2000044681A2 (en) * | 1999-02-01 | 2000-08-03 | The Curators Of The University Of Missouri | Method for preparing porous shells or gels from glass particles |
WO2001082875A2 (en) * | 2000-05-01 | 2001-11-08 | Aeropharm Technology, Inc. | A core formulation |
WO2003005993A1 (en) * | 2000-05-01 | 2003-01-23 | Aeropharm Technology Incorporated | Core formulation comprising troglitazone and a biguanide |
WO2003005991A1 (en) * | 2001-07-10 | 2003-01-23 | Aeropharm Technology Incorporated | A core formulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
-
2001
- 2001-07-10 CA CA002453775A patent/CA2453775A1/en not_active Abandoned
- 2001-07-10 EP EP01952548A patent/EP1429747A4/en not_active Withdrawn
- 2001-07-10 WO PCT/US2001/021615 patent/WO2003005995A1/en not_active Application Discontinuation
- 2001-07-10 JP JP2003511802A patent/JP2004536843A/ja active Pending
- 2001-07-10 AU AU2001273289A patent/AU2001273289B2/en not_active Ceased
- 2001-07-10 MX MXPA04000180A patent/MXPA04000180A/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041842A1 (en) * | 1996-05-09 | 1997-11-13 | The Trustees Of The University Of Pennsylvania | Hollow bone mineral-like calcium phosphate particles |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
WO1999003477A1 (en) * | 1997-07-18 | 1999-01-28 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
WO2000044681A2 (en) * | 1999-02-01 | 2000-08-03 | The Curators Of The University Of Missouri | Method for preparing porous shells or gels from glass particles |
WO2001082875A2 (en) * | 2000-05-01 | 2001-11-08 | Aeropharm Technology, Inc. | A core formulation |
WO2003005993A1 (en) * | 2000-05-01 | 2003-01-23 | Aeropharm Technology Incorporated | Core formulation comprising troglitazone and a biguanide |
WO2003005991A1 (en) * | 2001-07-10 | 2003-01-23 | Aeropharm Technology Incorporated | A core formulation |
Non-Patent Citations (1)
Title |
---|
See also references of WO03005995A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2001273289B2 (en) | 2004-10-07 |
JP2004536843A (ja) | 2004-12-09 |
CA2453775A1 (en) | 2003-01-23 |
EP1429747A1 (en) | 2004-06-23 |
MXPA04000180A (es) | 2004-11-22 |
WO2003005995A1 (en) | 2003-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2375299B (en) | Playard and a changing table thereof | |
EP1455793A4 (en) | ANTI-DIABETAL FORMULATION AND METHOD | |
IL158437A0 (en) | Absorbent article having a multilayer absorbent core | |
HK1136780A1 (en) | Multistage formulation containing a biguanide and thiazolidindione derivatives | |
AU2001227535A8 (en) | A core formulation | |
PL370563A1 (en) | Deuterated substituted pyrazolylbenzylsulfonamides and medicaments comprising said compounds | |
AU2002337749A1 (en) | Pioglitazone hydrochloride | |
EP1429747A4 (en) | CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE | |
TWI315982B (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
EP1511753A4 (en) | ANTIMICROBIAL MEDIUM AND ITS USE | |
HK1052281A1 (en) | Method and device for manufacturing brush | |
EP1429732A4 (en) | CORE FORMULATION | |
EP1429740A4 (en) | CORE FORMULATION WITH TROGLITAZONE AND A BIGUANIDE | |
AU2001273309A1 (en) | Core formulation comprising troglitazone and a biguanide | |
GB0111723D0 (en) | A pillow | |
SG104988A1 (en) | Leadframe and component with a leadframe | |
GB0013400D0 (en) | A formulation | |
IL147063A0 (en) | Pesticidal formulation | |
IL161496A0 (en) | A combination product comprising melagatran and dexamethasone | |
AU2001269849A1 (en) | A package and methods of manufacturing and using same | |
GB2372253B (en) | A render | |
GB0201663D0 (en) | A puzzle | |
GB2384987B (en) | A head lice formulation | |
GB0030802D0 (en) | Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrochloride | |
HU0105205D0 (en) | Pharmaceutical composition with combined active agents containing metformin and a hydroxylamine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041122 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 9/50 B Ipc: 7A 61K 31/4439 B Ipc: 7A 61K 31/155 B Ipc: 7A 61K 9/16 A |
|
17Q | First examination report despatched |
Effective date: 20050323 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060131 |